Metformin therapy and risk of cancer in patients after heart transplantation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F21%3A00075813" target="_blank" >RIV/00159816:_____/21:00075813 - isvavai.cz</a>
Alternative codes found
RIV/00209775:_____/21:N0000005 RIV/00216224:14110/21:00124032
Result on the web
<a href="http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1" target="_blank" >http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/BLL_2021_051" target="_blank" >10.4149/BLL_2021_051</a>
Alternative languages
Result language
angličtina
Original language name
Metformin therapy and risk of cancer in patients after heart transplantation
Original language description
BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to find out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient's survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a significantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19). Text in PDF www.elis.sk
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30218 - General and internal medicine
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Bratislavské Lekárske Listy
ISSN
0006-9248
e-ISSN
—
Volume of the periodical
122
Issue of the periodical within the volume
5
Country of publishing house
SK - SLOVAKIA
Number of pages
5
Pages from-to
305-309
UT code for WoS article
000647174500002
EID of the result in the Scopus database
—